Glenmark Pharmaceuticals poised to launch Zanubrutinib in India

Glenmark Pharmaceuticals is set to launch Zanubrutinib in India, following its approval from the Drugs Controller General of India (DCGI).

Zanubrutinib will be locally marketed as Brukinsa, an innovative therapy developed by BeiGene (now BeOne Medicines), a global oncology leader delivering advanced treatments for cancer patients worldwide, a note from Glenmark said.

“We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines),” said Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals.  

The introduction of Brukinsa brings an innovative treatment option at a time when India faces a significant burden from serious and difficult-to-treat haematological malignancies, the company said. Brukinsa is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL), it added.

The product is approved in over 70 countries, with clinical evidence from trials including ALPINE, ASPEN, and SEQUOIA, the note said.  

Adam Roach, Senior Vice President and Head of Japan and Asia Pacific region for BeiGene (to be renamed BeOne Medicines) added, Brukinsa introduction in India was part of its efforts to expand patient access to innovative oncology treatments across the Asia Pacific region.

Published on June 9, 2025